Understanding your FASLODEX treatment

Whether you’re considering FASLODEX with your doctor or are already receiving FASLODEX, it’s important to understand how your medicine works—and what that means for your metastatic breast cancer journey.

What is FASLODEX?

FASLODEX is a medicine for postmenopausal women with hormone receptor-positive metastatic breast cancer with disease progression after antiestrogen therapy. When taken with palbociclib, it’s used to treat women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer whose disease has spread to other parts of the body (metastatic) with disease progression after hormonal therapy.

Regardless of whether it is used alone or with palbociclib, FASLODEX works in the same way: by targeting the estrogen receptor and impacting cancer growth.

Now, let’s break down some of those terms.

icons_4-35

The estrogen receptor

The estrogen receptor—visually represented near this text—can influence the growth of hormone receptor-positive metastatic breast cancer. FASLODEX can connect* with estrogen receptors much like how a baseball connects with a glove: by fitting into a specialized receiver.

*FASLODEX does not bind to 100% of estrogen receptors.

 
icons_4-20

Hormone receptor-positive

Hormone receptor-positive cancer cells depend on hormone receptors, such as estrogen receptors, to grow. Your doctor may also use the term estrogen receptor-positive.

 
icons_4-19

Human epidermal growth factor receptor 2-negative

Human epidermal growth factor receptor 2-negative cancer cells do not depend on human epidermal growth factor receptor 2 to grow.

 

Estrogen receptors in estrogen receptor-positive metastatic breast cancer

The estrogen receptor can play a role in the spread of estrogen receptor-positive metastatic breast cancer by:

  • Connecting with estrogen, which can send signals that may cause the spread of cancer
  • Sending signals throughout metastatic breast cancer cells that do not rely on estrogen to activate
  • Participating in the process tumor cells undergo as they divide, which is called the cell cycle

Because the estrogen receptor can support tumor cell division in several ways, you and your doctor may want to consider a treatment that targets the estrogen receptor—such as FASLODEX.

Learn more about how FASLODEX works

FASLODEX acts on the estrogen receptor

Select an option below to learn more about the impact FASLODEX can have on hormone receptor-positive metastatic breast cancer growth. FASLODEX is the only approved hormonal medicine that has been shown to interact with the estrogen receptor in these ways.

Bind to the estrogen receptor

icons_4-25

When FASLODEX binds to estrogen receptors,* those estrogen receptors can react by:

  • Losing stability, meaning they will not work as well
  • Changing shape, affecting their ability to bind to estrogen

*As demonstrated in lab studies.

 
icons_4-36

FASLODEX impacts the way estrogen receptors work by binding to them.

 

Block estrogen receptor activation

icons_4-26

Estrogen receptors that are connected to FASLODEX have a reduced ability to activate or communicate with estrogen. Inactive estrogen receptors cannot participate in cancer growth.

 
icons_4-36

FASLODEX interferes with estrogen receptors’ ability to activate.

 

Degrade the estrogen receptor

icons_4-21

Estrogen receptors bound to FASLODEX break down quickly, resulting in fewer estrogen receptors in cancer cells.

 
icons_4-36

Broken down estrogen receptors cannot participate in the process of cancer growth.

 

Decrease the number of estrogen receptors

icons_4-27

When FASLODEX decreases the number of available estrogen receptors in breast cancer cells, estrogen receptors’ ability to cause cancer cells to divide and multiply is impacted.

FASLODEX is associated with a decrease in Ki67, a marker of cancer growth.

 
icons_4-36

Having fewer available estrogen receptors makes it more difficult for estrogen receptors to support cancer growth.

 

IMPORTANT SAFETY INFORMATION

  • You should not receive FASLODEX if you have had an allergic reaction to any of the ingredients in FASLODEX. Symptoms of an allergic reaction to FASLODEX may include: itching; swelling of your face, lips, tongue, or throat; trouble breathing
  • Before receiving FASLODEX, tell your healthcare provider about all of your medical conditions, including if you:

  • Have a low level of platelets in your blood or bleed easily. Especially tell your healthcare provider if you take a blood thinner medicine (anticoagulants)
  • Have liver problems
  • Are pregnant or plan to become pregnant, as FASLODEX can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment with FASLODEX and for one year after the last dose. Tell your healthcare provider right away if you become pregnant or think you are pregnant while on FASLODEX
  • Are breast-feeding or plan to breast-feed. It is not known if FASLODEX passes into breast milk. Do not breast-feed during treatment with FASLODEX and for one year after the last dose. Talk to your healthcare provider about the best way to feed your baby during this time
  • FASLODEX is administered as a shot into the muscle of your buttock.

    FASLODEX may cause injection site related nerve damage. Call your healthcare provider if you develop any of the following symptoms in your legs following a FASLODEX injection: numbness; tingling; weakness.

    The most common side effects of FASLODEX include: injection site pain; nausea; muscle, joint, and bone pain; headache; tiredness; hot flashes; vomiting; loss of appetite; weakness; cough; shortness of breath, constipation; and increased liver enzymes.

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with FASLODEX. For more information, ask your healthcare provider or pharmacist.

Approved Uses for FASLODEX

FASLODEX is a prescription medicine used to treat:

  • hormone receptor (HR)-positive breast cancer in women who have gone through menopause whose disease has spread after treatment with antiestrogen medicine, OR
  • HR-positive, human epidermal growth factor receptor 2 (HER2)‐negative breast cancer whose disease has spread to other parts of the body (metastatic) in combination with palbociclib in women with disease progression after hormonal therapy
  • When FASLODEX is used in combination with palbociclib, please also see the palbociclib Patient Information.

Please see FASLODEX Prescribing Information with Patient Information.

 
 
Read More

IMPORTANT SAFETY INFORMATION

  • You should not receive FASLODEX if you have had an allergic reaction to any of the ingredients in FASLODEX. Symptoms of an allergic reaction to FASLODEX may include: itching; swelling of your face, lips, tongue, or throat; trouble breathing
  • Before receiving FASLODEX, tell your healthcare provider about all of your medical conditions, including if you:

  • Have a low level of platelets in your blood or bleed easily. Especially tell your healthcare provider if you take a blood thinner medicine (anticoagulants)
  • Have liver problems
  • Are pregnant or plan to become pregnant, as FASLODEX can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment with FASLODEX and for one year after the last dose. Tell your healthcare provider right away if you become pregnant or think you are pregnant while on FASLODEX
  • Are breast-feeding or plan to breast-feed. It is not known if FASLODEX passes into breast milk. Do not breast-feed during treatment with FASLODEX and for one year after the last dose. Talk to your healthcare provider about the best way to feed your baby during this time
  • FASLODEX is administered as a shot into the muscle of your buttock.

    FASLODEX may cause injection site related nerve damage. Call your healthcare provider if you develop any of the following symptoms in your legs following a FASLODEX injection: numbness; tingling; weakness.

    The most common side effects of FASLODEX include: injection site pain; nausea; muscle, joint, and bone pain; headache; tiredness; hot flashes; vomiting; loss of appetite; weakness; cough; shortness of breath, constipation; and increased liver enzymes.

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with FASLODEX. For more information, ask your healthcare provider or pharmacist.

Approved Uses for FASLODEX

FASLODEX is a prescription medicine used to treat:

  • hormone receptor (HR)-positive breast cancer in women who have gone through menopause whose disease has spread after treatment with antiestrogen medicine, OR
  • HR-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer whose disease has spread to other parts of the body (metastatic) in combination with palbociclib in women with disease progression after hormonal therapy
  • When FASLODEX is used in combination with palbociclib, please also see the palbociclib Patient Information.